Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTABLETGeneric

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE

Standard Dose
EQ 50MG BASE; 300MG; 25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 212527 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE Form and strength TABLET - EQ 50MG BASE; 300MG; 25MG Sponsor CIPLA USA INC.

Structured Monograph

Clinical summary

Approval overview DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE is listed in Drugs@FDA under application 212527 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient DOLUTEGRAVIR LAMIVUDINE TENOFOVIR ALAFENAMIDE Form and strength TABLET - EQ 50MG BASE; 300MG; 25MG Sponsor CIPLA USA INC. Submission history Latest submission status date: 2022-03-30 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.